Abstract
We have characterized comprehensive transcript and proteomic profiles of cell lines corresponding to normal breast (MCF10A), noninvasive breast cancer (MCF7) and invasive breast cancer (MDA-MB-231). The transcript profiles were first analysed by a modified protocol for representational difference analysis (RDA) of cDNAs between MCF7 and MDA-MB-231 cells. The majority of genes identified by RDA showed nearly complete concordance with microarray results, and also led to the identification of some differentially expressed genes such as lysyl oxidase, copper transporter ATP7A, EphB6, RUNX2 and a variant of RUNX2. The altered transcripts identified by microarray analysis were involved in cell–cell or cell–matrix interaction, Rho signaling, calcium homeostasis and copper-binding/sensitive activities. A set of nine genes that included GPCR11, cadherin 11, annexin A1, vimentin, lactate dehydrogenase B (upregulated in MDA-MB-231) and GREB1, S100A8, amyloid β precursor protein, claudin 3 and cadherin 1 (downregulated in MDA-MB-231) were sufficient to distinguish MDA-MB-231 from MCF7 cells. The downregulation of a set of transcripts for proteins involved in cell–cell interaction indicated these transcripts as potential markers for invasiveness that can be detected by methylation-specific PCR. The proteomic profiles indicated altered abundance of fewer proteins as compared to transcript profiles. Antisense knockdown of selected transcripts led to inhibition of cell proliferation that was accompanied by altered proteomic profiles. The proteomic profiles of antisense transfectants suggest the involvement of peptidyl-prolyl isomerase, Raf kinase inhibitor and 80 kDa protein kinase C substrate in mediating the inhibition of cell proliferation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Akiri G, Sabo E, Dafni H, Vadasz Z, Kartvelishvily Y, Gan N et al. (2003). Cancer Res 63: 1657–1666.
Alpan RS, Sparvero S, Pardee AB . (1996). Mol Med 2: 469–478.
Amuthan G, Biswas G, Ananadatheerthavarada HK, Vijayasarathy C, Shephard HM, Avadhani NG . (2002). Oncogene 21: 7839–7849.
Baskaran N, Kandpal RP, Bhargava AK, Glynn MW, Bale A, Weissman SM . (1996). Genome Res 6: 633–638.
Becker M, Sommer A, Kratzschmar JR, Seidel H, Pohlenz HD, Fichtner I . (2005). Mol Cancer Ther 4: 151–168.
Berger M, Stahl N, Del Sal G, Haupt Y . (2005). Mol Cell Biol 25: 5380–5388.
Bieche I, Champeme MH, Lidereau R . (1995). Clin Cancer Res 1: 123–127.
Campbell FC, Blamey RW, Woolfson AM, Elston CW, Hosking DJ . (1983). Br J Surg 70: 202–204.
Cerosaletti KM, Shapero MH, Fournier RE . (1995). Genomics 25: 226–237.
Costa FF, Verbisck NV, Salim AC, Ierardi DF, Pires LC, Sasahara RM et al. (2004). Oncogene 23: 1481–1488.
Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T et al. (2002). Cancer Res 62: 1139–1147.
Fletcher GC, Patel S, Tyson K, Adam PJ, Schenker M, Loader JA et al. (2003). Br J Cancer 88: 579–585.
Fox BP, Kandpal RP . (2004). Biochem Biophys Res Commun 318: 882–892.
Hall J . (2005). Cancer Lett 227: 105–114.
Jacob AN, Baskaran N, Kandpal G, Narayan D, Bhargava AK, Kandpal RP . (1997). Somatic Cell Mol Genet 23: 83–95.
Johnson JP . (1991). Metast Rev 10: 11–22, Review.
Jones CE, Abdelraheim SR, Brown DR, Viles JH . (2004). J Biol Chem 279: 32018–32027.
Katoh M . (2003). Int J Mol Med 12: 3–9.
Keller ET, Fu Z, Yeung K, Brennan M . (2004). Cancer Lett 207: 131–137.
Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F et al. (2001). Nat Med 7: 673–679.
Kousidou OC, Roussidis AE, Theocharis AD, Karamanos NK . (2004). Anticancer Res 24: 4025–4030.
Lisitsyn N, Lisitsyn N, Wigler M . (1993). Science 259: 946–951.
Luo C, Shaw KT, Raghavan A, Aramburu J, Garcia-Cozar F, Perrino BA et al. (1996). Proc Natl Acad Sci USA 93: 8907–8912.
Malliri A, Collard JG . (2003). Curr Opin Cell Biol 15: 583–589.
Mantovani F, Gostissa M, Collavin L, Del Sal G . (2004). Cell Cycle 3: 905–911.
Marenholz I, Heizmann CW, Fritz G . (2004). Biochem Biophys Res Commun 322: 1111–1122.
Missiaen L, Robberecht W, van den Bosch L, Callewaert G, Parys JB, Wuytack F et al. (2000). Cell Calcium 28: 1–21.
Moller LB, Bukrinsky JT, Molgaard A, Paulsen M, Lund C, Tumer Z et al. (2005). Hum Mutat 26: 84–93.
Nagaraja GM, Kandpal RP . (2004). Biochem Biophys Res Commun 313: 654–665.
Pase L, Voskoboinik I, Greenough M, Camakaris J . (2004). Biochem J 378: 1031–1037.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. (2000). Nature 406: 747–752.
Pratap J, Galindo M, Zaidi SK, Vradii D, Bhat BM, Robinson JA et al. (2003). Cancer Res 63: 5357–5362.
Reiner A, Yekutieli D, Benjamini Y . (2003). Bioinformatics 19: 368–375.
Ridley AJ . (2004). Breast Cancer Res Treat 84: 13–19.
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. (2002). N Engl J Med 346: 1937–1947.
Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P et al. (2000). Nat Genet 24: 227–235.
Shao Q, Wang H, McLachlan E, Veitch GI, Laird DW . (2005). Cancer Res 65: 2705–2711.
Siegel RC . (1976). J Biol Chem 251: 5786–5792.
Takayama Y, Kamimura Y, Okawa M, Muramatsu S, Sugino A, Araki H . (2003). Genes Dev 17: 1153–1165.
van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. (2002). Nature 415: 530–536.
Warner SL, Bearss DJ, Han H, Von Hoff DD . (2003). Mol Cancer Ther 2: 589–595.
Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB et al. (2002). Mol Cell Biol 22: 7982–7992.
Wiseman A . (2005). Med Hypotheses 65: 32–34.
Yoshida S, Mears AJ, Friedman JS, Carter T, He S, Oh E et al. (2004). Hum Mol Genet 13: 1487–1503.
Yu YX, Heller A, Liehr T, Smith CC, Aurelian L . (2001). Int J Oncol 18: 905–911.
Acknowledgements
This research was supported in part by Faculty Research Award, Ames Faculty Award and a grant from the Department of Defense (RPK). We thank Dr M Hamilton for helpful discussions on proteomics.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nagaraja, G., Othman, M., Fox, B. et al. Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 25, 2328–2338 (2006). https://doi.org/10.1038/sj.onc.1209265
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209265
Keywords
This article is cited by
-
Expression signature and molecular basis of CDH11 in OSCC detected by a combination of multiple methods
BMC Medical Genomics (2023)
-
Mitochondrial copper depletion suppresses triple-negative breast cancer in mice
Nature Biotechnology (2021)
-
Impact of isolation methods on the biophysical heterogeneity of single extracellular vesicles
Scientific Reports (2020)
-
Unraveling FATP1, regulated by ER-β, as a targeted breast cancer innovative therapy
Scientific Reports (2019)
-
Beyond DNA: the Role of Epigenetics in the Premalignant Progression of Breast Cancer
Journal of Mammary Gland Biology and Neoplasia (2018)